SECsense Logo

Eli Lilly & Co. 8-K Report: Insights on Debt Instruments and Financial Obligations

$LLY
Form 8-K
Filed on: 2025-02-12
Source
Eli Lilly & Co. 8-K Report: Insights on Debt Instruments and Financial Obligations

Here are the key insights extracted from the provided financial report section:

  1. Company Identification:
  • Company: Eli Lilly & Co.
  • SEC CIK: 0000059478
  • Address: Lilly Corporate Center, Indianapolis, IN 46285
  • Contact: (317) 276-2000
  1. Report Type:
  • Filing Type: 8-K
  • Filing Date: February 10, 2025
  1. Stock Information:
  • Common Stock: No par value, traded under ticker LLY on NYSE.
  1. Debt Instruments: The report outlines various notes issued by Eli Lilly & Co., with their respective due dates and interest rates:
  • 7 1/8% Notes due 2025 (LLY25)
  • 1.625% Notes due 2026 (LLY26)
  • 2.125% Notes due 2030 (LLY30)
  • 0.625% Notes due 2031 (LLY31)
  • 0.500% Notes due 2033 (LLY33)
  • 6.77% Notes due 2036 (LLY36)
  • 1.625% Notes due 2043 (LLY43)
  • 1.700% Notes due 2049 (LLY49A)
  • 1.125% Notes due 2051 (LLY51)
  • 1.375% Notes due 2061 (LLY61)
  1. Reporting Context:
  • The context for the data covers a specific date: February 10, 2025.
  • The reporting structure indicates multiple segments related to different classes of stock and notes due, suggesting detailed tracking of liabilities and equity.
  1. Financial Reporting Standards:
  • The report adheres to US GAAP standards, with explicit members defined for various classes of stock and notes.

Summary

The filing indicates that Eli Lilly & Co. has a range of debt securities with varying interest rates and due dates, reflecting its capital structure and obligations. The presence of multiple notes suggests a strategy for managing financial liabilities while balancing costs associated with debt. Overall, this filing provides a snapshot of the company's current financial obligations and its equity structure as of February 10, 2025.